Notice of Intent: LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), specifically the Healthcare Contracting Division – Northeast (HCD-NE) at Walter Reed National Military Medical Center (WRNMMC), has issued a Notice of Intent to award a firm fixed-price, sole-source contract to Novartis Pharmaceuticals Corporation (Cage: 04520). This action is for the procurement of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan). This notice is not a request for competitive proposals.
Scope of Work
The contract is intended to procure two specific pharmaceutical products:
- LUTATHERA® (lutetium Lu 177 dotatate)
- PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) These products are exclusively developed, manufactured, and supplied by Novartis Pharmaceuticals Corporation.
Contract & Timeline
- Type: Firm Fixed-Price, Sole Source (Notice of Intent)
- Intended Awardee: Novartis Pharmaceuticals Corporation
- Authority: FAR 6.302-1 "Only one responsible source and no other supplies or services will satisfy agency requirements"
- Set-Aside: None (Sole Source)
- Response Due: June 4, 2026, by 5:00 PM (ET)
- Published: May 14, 2026
Evaluation
Information received from interested parties will be considered solely to determine if conducting a competitive procurement is in the best interest of the Government. This notice does not constitute a solicitation, and requests for copies of a solicitation will not be honored.
Additional Notes
Interested parties capable of providing these specific drugs may identify their interest and capabilities by emailing claudia.a.febresmormontoy.ctr@health.mil by the response deadline. All submitted information should support the offeror's capability and must be furnished at no cost or obligation to the Government. Phone calls will not be accepted.